Register for our free email digests:
Simcere Pharmaceutical Group
www.simcere.com
Latest From Simcere Pharmaceutical Group
Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
Deal Watch: Another Delay For Roche/Spark, While FTC Ups AbbVie/Allergan Merger Scrutiny
Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.
Asia Deal Watch: ASLAN, Bukwang Establish Immuno-Oncology JV In Singapore
The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.
Asia Executives On The Move: Senior Level Changes At Pfizer Upjohn, Simcere In China
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Vaccines
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Asia
-
China
-
China
-
Asia
- Parent & Subsidiaries
- Simcere Pharmaceutical Group
- Senior Management
-
Jinsheng Ren, CEO
Wan Yushan, CFO
Hua Mu, MD, PhD, CSO - Contact Info
-
Simcere Pharmaceutical Group
Phone: (86) 025 855 66666
699-18 Xuanwu Ave.
Nanjing, 210042
China
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice